Pharmaceutical

“Pharma firms hold billions in IP, R&D advances and patient data—making them prime targets.”

Cyber Security Challenges

Industry 4.0 brings automation and efficiency but exposes OT systems—bioreactors, DCS, SCADA—to new vulnerabilities once air-gapped.

ICS/OT malware like Industroyer, Triton and Incontroller proves attackers are targeting critical pharmaceutical infrastructure.

Situational Awareness

Perception (What’s happening?)

Malware and ransomware attacks on control and safety systems are on the rise.
System obsolescence, expanded connectivity and workforce OT-awareness gaps exacerbate risks.
Smart sensors and supply-chain integrations widen the attack surface rapidly.

Comprehension (Why does it matter?)

Compromised OT can halt production, endanger patients, and endanger staff safety.
Theft of IP and “crown jewel” data can destroy competitive advantage and invite regulatory penalties.

Risk Management

We recommend a two-phase, holistic OT risk program:

Phase 1 – Risk Identification & Prioritization
Map critical OT functions (bioreactors, chromatography), assess impact, and involve custodians and engineers to chart real-world attack paths—covering architecture, access, third-party scope, supply chain, and physical security.

Phase 2 – OT Cybersecurity Framework (OT-CSF)
Build formal policies, procedures, and playbooks aligned to:

ISA/IEC 62443
NIST CSF
NERC-CIP
ISO/IEC 27001/27002/27019

Core elements:

Governance model (RACI roles)
End-to-end operating model
Regulatory compliance mapping
Asset inventory
Network diagrams
Incident response plans
Workforce training & awareness
Procedural controls (access, change, backup)
Monitoring & reporting

Mature with audits, threat detectors, vulnerability monitoring, supplier clauses and PAM.

Ensure funding, skills, vendor support and governance to sustain OT resilience.